GSK plc (NYSE:GSK) Stake Boosted by Outlook Wealth Advisors LLC

Outlook Wealth Advisors LLC boosted its holdings in shares of GSK plc (NYSE:GSK) by 18.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,422 shares of the pharmaceutical company’s stock after acquiring an additional 1,163 shares during the quarter. Outlook Wealth Advisors LLC’s holdings in GSK were worth $318,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Raymond James & Associates lifted its holdings in shares of GSK by 5.6% during the first quarter. Raymond James & Associates now owns 1,187,964 shares of the pharmaceutical company’s stock worth $50,928,000 after buying an additional 62,899 shares during the last quarter. First Trust Direct Indexing L.P. raised its position in shares of GSK by 4.5% during the first quarter. First Trust Direct Indexing L.P. now owns 25,128 shares of the pharmaceutical company’s stock valued at $1,077,000 after buying an additional 1,078 shares during the last quarter. Abundance Wealth Counselors lifted its stake in shares of GSK by 7.3% in the first quarter. Abundance Wealth Counselors now owns 19,816 shares of the pharmaceutical company’s stock valued at $850,000 after buying an additional 1,343 shares during the period. JTC Employer Solutions Trustee Ltd grew its position in GSK by 71.3% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock worth $909,063,000 after buying an additional 8,800,822 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new position in GSK during the first quarter valued at about $219,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Jefferies Financial Group upgraded GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Morgan Stanley assumed coverage on shares of GSK in a research note on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Finally, Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

GSK Price Performance

Shares of NYSE:GSK traded up $0.20 on Friday, hitting $41.11. The stock had a trading volume of 2,730,464 shares, compared to its average volume of 2,904,690. The firm’s 50 day moving average price is $41.83 and its 200-day moving average price is $38.95. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88. GSK plc has a twelve month low of $33.33 and a twelve month high of $43.84. The company has a market capitalization of $85.20 billion, a price-to-earnings ratio of 13.66, a price-to-earnings-growth ratio of 1.44 and a beta of 0.64.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The firm had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. On average, equities research analysts predict that GSK plc will post 4.03 earnings per share for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Stockholders of record on Friday, February 23rd were given a dividend of $0.3564 per share. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.47%. This is a positive change from GSK’s previous quarterly dividend of $0.34. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s dividend payout ratio is presently 52.82%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.